Risk for Reoperation After First MTP Joint Arthrodesis

NCT ID: NCT05795127

Last Updated: 2024-02-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1213 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-01

Study Completion Date

2028-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We will screen all first metatarsophalangeal joint arthrodeses performed between 2010 and 2022 in Helsinki University Hospital. Information about demographics and additional diagnoses will be yielded from data pool of medical records. Additionally we review pre- and post-operative x-rays for first MTP joint angles and OR records for operative techniques.

Our aim is to find associations between those known variables and risk for reoperation in two years after operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The number of primary surgery in the adult population (age 18 years or older) will be collected from patient information systems using the NOMESCO procedure code NHG80 regardless of diagnosis. These patients will be further screened for diabetes and arthritic diseases (the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes E10.\*\*-E14.\*\* and M05.\*\*-M14.\*\*). As reoperations will be considered surgery under the NOMESCO procedure codes NH\*\*\*, QDB\*\*\*, QDG\*\*\*, ZZH\*\*\*. Comorbidities were collected from the previous patient health records by diagnosis codes for diabetes type 1 (E10.\*\*), other diabetes (E11.\*\*-14.\*\*), seropositive rheumatoid arthritis (M05.9), seronegative rheumatoid arthritis (M06.0), psoriasis (M07.\*\*), gout (M10.\*\*), other arthritis (M09.\*\*, M11-M14).

The data will be divided and analyzed in two separate phases. First we will gather all the information that we can reliably utilize from the register. The data will include the primary operation, all reoperations, experience level of the surgeon, patients' age, sex, and whether the patient has been diagnosed with other comorbidities stated above.

In the second phase, we will collect matched patients for the patients who underwent reoperations using propensity score matching with ratio of 1:3 with nearest neighbour method. The variables used for matching will be age, sex and all other comorbidities (diabetes type 1, other diabetes, seropositive rheumatoid arthritis, seronegative rheumatoid arthritis, psoriasis, gout, other arthritis) We will further screen the medical records of the reoperated patients as well the matched controls. From pre- and post-operative x-rays we will determine the degree of arthrosis and hallux valgus and intermetatarsal angles. Operation reports will be screened for surgical technique (i.e. method of cartilage removal, fixation and use of bone transport). These data will be used to analyze the association of perioperative factors and reoperations. These models will not be including variables that were used in matching.

During the both phases, we will use logistic regression to analyze association between assumed risk factors and reoperations by using the data from the register (first phase) or from the patients' health records and x-rays (second phase). We will evaluate causality with directed acyclic graphs (DAG), and develop logistic models separately for each of the assumed risk factors. The variables used in the DAGs will be selected based on previous knowledge and hypothesized causal relationships. Results from both analyses will interpreted with adjusted odds ratios (OR) with 95 % confidence intervals (CI). Model fit will be assessed by McFadden R2 -index, multicollinearity by evaluating Variance Inflation Factor (VIF) and heteroscedasticity by inspecting the fitted values vs. residual plots. Statistical analyses will be performed with R version 4.0.5.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hallux Rigidus Orthopedic Disorder Surgery Complication of Surgical Procedure Hallux Valgus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reoperated

Primary arthrodesis operations later requiring reoperation.

First metatarsophalangeal joint arthrodesis

Intervention Type PROCEDURE

Surgery leadin to bony uninon in firts metatarsophalangeal joint

Control

Primary arthrodesis operations with no further operations. Size of the control group is four fold.

First metatarsophalangeal joint arthrodesis

Intervention Type PROCEDURE

Surgery leadin to bony uninon in firts metatarsophalangeal joint

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

First metatarsophalangeal joint arthrodesis

Surgery leadin to bony uninon in firts metatarsophalangeal joint

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

First MTPJ arthrodesis

Exclusion Criteria

none
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital District of Helsinki and Uusimaa

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mikko Miettinen

M.D., Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Helsinki University Hospital

Helsinki, , Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HUS/206/2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HTO With and Without Arthroscopy
NCT00284622 UNKNOWN PHASE2